Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

tilsotolimod sodium

A proprietary synthetic oligonucleotide-based agonist of toll-like receptor 9 (TLR9), with potential immunostimulating activity. Upon administration, tilsotolimod sodium binds to and activates TLR9 expressed by plasmacytoid dendritic cells (pDCs) and B cells. This initiates immune signaling pathways, activates B cells and pDCs, and induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. TLR9 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	TLR9 agonist IMO-2125
Code name:	IMO 2125 IMO-2125

tilsotolimod sodium

Search NCI's Drug Dictionary